Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. Recently, I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies. In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s recently launched AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy! [Read more…]
In major news released last week, Minerva Biotechnologies announced a “major breakthrough for stem cell research and therapies – a simple method of inducing naïve state pluripotency in human stem cells.” While induced pluripotent stem cell (iPSC) techniques can reprogram an adult cell to a stem cell-like state, Minerva has discovered a “primitive growth factor, NME7-AB, that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state.”
This finding is a continuation of ongoing innovation occurring in the area of stem cell research and applications.
To learn more, read the full press release below. [Read more…]